Dr. Saqib Abbasi

Claim this profile

University of Kansas Cancer Center

Studies Bladder Cancer
Studies Urothelial Carcinoma
3 reported clinical trials
10 drugs studied

Area of expertise

1Bladder Cancer
Saqib Abbasi has run 3 trials for Bladder Cancer. Some of their research focus areas include:
Stage IV
Stage III
2Urothelial Carcinoma
Saqib Abbasi has run 2 trials for Urothelial Carcinoma. Some of their research focus areas include:
Stage IV
Stage III

Affiliated Hospitals

Image of trial facility.
University Of Kansas Cancer Center
Image of trial facility.
University Of Kansas Cancer Center-Overland Park

Clinical Trials Saqib Abbasi is currently running

Image of trial facility.

Eribulin + Chemotherapy

for Bladder Cancer

This phase III trial compares the usual chemotherapy treatment to eribulin plus gemcitabine in treating patients with urothelial cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Chemotherapy drugs, such as eribulin, gemcitabine, docetaxel, paclitaxel, and sacituzumab govitecan work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial aims to see whether adding eribulin to standard of care chemotherapy may work better in treating patients with metastatic urothelial cancer.
Recruiting2 awards Phase 3
Image of trial facility.

Blood Test and Immunotherapy

for Bladder Cancer

This phase II/III trial examines whether patients who have undergone surgical removal of bladder, kidney, ureter or urethra, but require an additional treatment called immunotherapy to help prevent their urinary tract (urothelial) cancer from coming back, can be identified by a blood test. Many types of tumors tend to lose cells or release different types of cellular products including their DNA which is referred to as circulating tumor DNA (ctDNA) into the bloodstream before changes can be seen on scans. Health care providers can measure the level of ctDNA in blood or other bodily fluids to determine which patients are at higher risk for disease progression or relapse. In this study, a blood test is used to measure ctDNA and see if there is still cancer somewhere in the body after surgery and if giving a treatment will help eliminate the cancer. Immunotherapy with monoclonal antibodies, such as nivolumab and relatlimab, can help the body's immune system to attack the cancer, and can interfere with the ability of tumor cells to grow and spread. This trial may help doctors determine if ctDNA measurement in blood can better identify patients that need additional treatment, if treatment with nivolumab prolongs patients' life and whether the additional immunotherapy treatment with relatlimab extends time without disease progression or prolongs life of urothelial cancer patients who have undergone surgical removal of their bladder, kidney, ureter or urethra.
Recruiting1 award Phase 2 & 310 criteria

More about Saqib Abbasi

Clinical Trial Related4 years of experience running clinical trials · Led 3 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Saqib Abbasi has experience with
  • Docetaxel
  • Eribulin Mesylate
  • Gemcitabine Hydrochloride
  • Paclitaxel
  • Avelumab
  • M6223

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Saqib Abbasi specialize in?
Is Saqib Abbasi currently recruiting for clinical trials?
Are there any treatments that Saqib Abbasi has studied deeply?
What is the best way to schedule an appointment with Saqib Abbasi?
What is the office address of Saqib Abbasi?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security